Alicia Morgans and Sandy Srinivas discuss selecting triplet therapy in metastatic hormone-sensitive prostate cancer. Dr. Morgans favors docetaxel triplets for de novo, high-volume disease, ...

The survival rate for the majority of patients with non-muscle invasive bladder cancer (NMIBC) is favorable; however, the rates of recurrence and progression to muscle-invasive bladder cancer are ...

Andrea Apolo presents a bone metastasis subanalysis from CheckMate-9ER, encompassing roughly 650 patients with metastatic clear cell renal cell carcinoma, around 25% of whom had bone metastases ...

This study demonstrates that the long noncoding RNA (lncRNA) LINC00460 is significantly overexpressed in clear cell renal cell carcinoma (ccRCC) and is strongly associated with adverse clinical ...

A contemporary standard of care for patients with metastatic androgen pathway modulator-naive/sensitive (APMN/S) prostate cancer (also known as metastatic hormone-sensitive prostate cancer) is ...

Michael Ong describes the TRIPLE-SWITCH trial design, a phase 3 study randomizing patients with metastatic hormone-sensitive prostate cancer and PSA of 0.2 or above at six to twelve months of ADT plus ...

To assess the efficacy of the prostatic urethral lift (PUL) procedure for treating lower urinary tract symptoms (LUTS) in men with a history of prostate irradiation. A retrospective review was ...

Alicia Morgans discusses ARACOG, a randomized trial comparing cognitive outcomes between darolutamide and enzalutamide in advanced prostate cancer. The study enrolled patients from 2021 to 2024 with ...

The publication of our phase 3 trial of aglatimagene besadenovec in The Lancet Oncology represents an important milestone in the treatment of localized prostate cancer. While the primary publication ...

Resistance to androgen receptor pathway inhibitors (ARPIs) necessitates development of regimens to improve outcomes in metastatic prostate cancer (mPC). This phase 1b clinical trial evaluated ...

Radiopharmaceutical therapy, a form of targeted radionuclide therapy, has emerged as a rapidly advancing area in prostate cancer management, with significant developments in 2025. The field, which ...

Radiopharmaceutical therapy with 225Ac-labeled prostate-specific membrane antigen (225Ac-PSMA) has shown promising results in patients with metastatic castration-resistant prostate cancer (mCRPC). To ...